Dopamine agonists alter neuroplasticity in LID

[Angela Cenci Nilsson]

Parkinson´s disease (PD) patients often receive combined pharmacotherapies where D2-class dopamine agonists are used as an adjunct to L-DOPA. We have now investigated the effects of this adjunct treatment at multiple levels and obtained some intriguing results…read the entire story in this paper:

Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Espa E, Song L, Skovgård K, Fanni S, Cenci MA. Mov Disord. 2023 Jan 19. doi: 10.1002/mds.29301. Online ahead of print.
PMID: 36656044

Attachments:

1. Espa-et-al_Mov-Dis-2023.pdf

[Webmaster]

Thank you for sharing this publication Angela!

[Author]

Posts